NexoBrid
- NexoBrid Wirkstoff
- Konzentrat proteolytischer Enzyme, angereichert mit Bromelain
- Bereich
- Wundreinigung
- Alternativen
- Keine
What is this? NexoBrid is a medicine used to clean burns. It contains enzymes from pineapple that help remove dead skin.
What's happening? There is a shortage of NexoBrid in the EU. Supplies may be limited or hard to find.
Does this affect me? If you need NexoBrid for a burn, talk to your doctor or pharmacist right away.
What should I do? Ask your pharmacist or doctor about other treatments while supplies are low.
🤖 Diese allgemeinverständliche Zusammenfassung wird automatisch aus der offiziellen Mitteilung der Behörde mithilfe von KI erstellt. Sie dient nur zur allgemeinen Information – nicht als medizinischer Rat. Treffen Sie gesundheitsbezogene Entscheidungen immer in Absprache mit einer Apothekerin oder einem Arzt und lesen Sie die verlinkte offizielle Quelle unten.
📋 Von der offiziellen Behördenmitteilung
Aktualisiert vor 1 Woche- Erstmals veröffentlicht
- 06/05/2026
- Betroffene Arzneimittel
- NexoBrid
- Lieferengpass-Status
- Ongoing
- Therapeutisches Gebiet (MeSH)
- Debridement
- Verfügbarkeit von Alternativen
- No
- Internationaler Freiname (INN) oder gebräuchlicher Name
- concentrate of proteolytic enzymes enriched in bromelain
Seiteninhalt
Engpässen-Information
There is a shortage of NexoBrid in some EU/EEA Member States.
NexoBrid is a medicine used for removing eschar (dead tissue which is dried out, thick, leathery and black) due to skin burns caused by heat or fire.
For further information on the use of the medicine, please refer to the medicine’s overview page.
In October 2025, MediWound Ltd., the manufacturer of NexoBrid, found a problem with a test used to check that the production of NexoBrid 5 g is sterile (clean and free from germs). The company is investigating the issue and, as a precautionary measure, has temporarily suspended the distribution of NexoBrid 5 g in the EU.
This has resulted in a temporary shortage of NexoBrid. In addition, the company has withdrawn NexoBrid 2 g from the EU market due to commercial reasons.
The shortage affects some of the Member States where the product is marketed: Austria, Belgium, Denmark, Finland, Germany, Italy, Norway, the Netherlands, Poland, Romania, Spain and Sweden.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority using the below links.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- There is an ongoing shortage of NexoBrid in some EU/EEA Member States which is expected to last until June 2026.
- If NexoBrid is not available, patients should be managed according to standard of care for wound treatment, including appropriate surgical debridement where indicated and the use of suitable wound dressings. Clinical management should be based on individual patient needs and current clinical guidelines.
- For additional information consult your country’s shortage register or contact your national competent authority.
- There is an ongoing shortage of NexoBrid in some EU/EEA Member States which is expected to last until June 2026.
- While the medicine is not available, your doctor will treat your wound according to standard guidelines for wound care. This usually includes careful cleaning of the wound by a healthcare professional and the use of appropriate dressings to support healing.
- Follow your healthcare provider’s advice for ongoing wound care and monitoring.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority using the below links.
Grund für Engpass
In October 2025, MediWound Ltd., the manufacturer of NexoBrid, found a problem with a test used to check that the production of NexoBrid 5 g is sterile (clean and free from germs). The company is investigating the issue and, as a precautionary measure, has temporarily suspended the distribution of NexoBrid 5 g in the EU.
This has resulted in a temporary shortage of NexoBrid. In addition, the company has withdrawn NexoBrid 2 g from the EU market due to commercial reasons.
Betroffene Mitgliedstaaten
The shortage affects some of the Member States where the product is marketed: Austria, Belgium, Denmark, Finland, Germany, Italy, Norway, the Netherlands, Poland, Romania, Spain and Sweden.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority using the below links.
Überwachung von Engpässen
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
Empfehlungen für medizinisches Fachpersonal
- There is an ongoing shortage of NexoBrid in some EU/EEA Member States which is expected to last until June 2026.
- If NexoBrid is not available, patients should be managed according to standard of care for wound treatment, including appropriate surgical debridement where indicated and the use of suitable wound dressings. Clinical management should be based on individual patient needs and current clinical guidelines.
- For additional information consult your country’s shortage register or contact your national competent authority.
Empfehlungen für Patient:innen und Betreuungspersonen
- There is an ongoing shortage of NexoBrid in some EU/EEA Member States which is expected to last until June 2026.
- While the medicine is not available, your doctor will treat your wound according to standard guidelines for wound care. This usually includes careful cleaning of the wound by a healthcare professional and the use of appropriate dressings to support healing.
- Follow your healthcare provider’s advice for ongoing wound care and monitoring.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority using the below links.
Wichtige Fakten
- Medicines affected
- NexoBrid
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- concentrate of proteolytic enzymes enriched in bromelain
- Therapeutic area (MESH)
- Debridement
- Availability of alternatives
- No
Wichtige Termine
- First published
Ähnliche medizinische Informationen
🔬 Medizinische / technische Details Für Fachkräfte
INN: concentrate of proteolytic enzymes enriched in bromelain · Area: Debridement · Alternatives: No
Alle Informationen auf dieser Seite stammen aus der offiziellen Agenturmitteilung. Wir übersetzen und fassen sie zusammen; wir ergänzen oder ändern keine Fakten.
